CNTN · Canton Strategic Holdings, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Active SV weight | 0.5 | as of June 30, 2026 | — |
| Adjusted EBITDA non-GAAP | -$820,449 | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net loss from continuing operations -$17,954,081
+$69,857 Stock based compensation
+$23,735,950 Unrealized loss from digital assets holdings
-$6,672,175 Provision (benefit) for income taxes
= Adjusted EBITDA -$820,449
|
|||
| Adjusted Operating Expenses non-GAAP | $2,628,156 | Three Months Ended June 30, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Operating Expenses $2,698,013
-$69,857 Less: stock based compensation
= Adjusted Operating Expenses $2,628,156
|
|||
| Adjusted Operating Expenses Coverage Ratio non-GAAP | 56.9% | Three Months Ended June 30, 2026 | — |
| Canton Coin holdings | 3,714,204,876 | as of June 30, 2026 | — |
| Total approved SV weight | 15 | as of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CNTN
this stock
Canton Strategic Holdings, Inc.
|
$168.13M | -30.4% | — | — | 9.8% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$129.29B | +12.5% | +46.2% | 29.7 | 1.8% |
|
MRNA
Moderna, Inc.
|
$89.83B | +663.0% | +4.3% | — | 7.7% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$76.86B | -3.3% | +20.8% | 18.5 | 2.1% |
|
CSLLY
Csl Ltd
|
$61.83B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CNTN | -6.2% | +0.0% | -39.9% | -11.2% | -30.4% |
| SPY | +1.2% | +1.9% | +9.9% | +2.1% | +14.2% |
| vs SPY | -7.4% | -1.9% | -49.8% | -13.3% | -44.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.